Luminary Therapeutics
Minneapolis, US · Founded 2019 · Delaware corporation · 1 known investors
Find your way into Luminary Therapeutics
Luminary Therapeutics is a clinical-stage biotech developing allogeneic CAR-T cell therapies built on its Gamma 2.0+ platform to treat solid tumors, B-cell malignancies, and B-cell-mediated autoimmune diseases. The company uses a Dual CAR architecture and the TcBuster transposon system to address relapse, T cell exhaustion, and high manufacturing costs.
Founders & leadership
Luminary Therapeutics was founded in 2019 by David Largaespada.
DL
David LargaespadaFounder
JL
Jeff LiterNamed on SEC filing
JH
James HaymakerNamed on SEC filing
Board
JR
Jeff RossBoard director
JW
John WellsBoard director
TL
Tracey LodieBoard director
MC
Mark ChanceBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$14.5M disclosed across 6 rounds · 2019–2025
▶$1.4MraisedNov 2025 · 6 investors · BiotechnologyRule 506(b)
▶$1.4MraisedNov 2025 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Branden MoriarityDirector
- Mark ChanceDirector
- Tracey LodieDirector
- James HaymakerDirector, Promoter
- John WellsDirector
- Jeff RossDirector
- Jeff LiterExecutive Officer, Director, Promoter
- Offering amount
- $12.4M
- Amount sold
- $1.4M
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.2MraisedJan 2025 · 49 investors · BiotechnologyRule 506(b)
▶$5.2MraisedJan 2025 · 49 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tracey LodieDirector
- Jeff LiterExecutive Officer, Director, Promoter
- Jeff RossDirector
- James HaymakerDirector, Promoter
- Mark ChanceDirector
- John WellsDirector
- Offering amount
- $5.5M
- Amount sold
- $5.2M
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.2MraisedJan 2025 · 48 investors · BiotechnologyRule 506(b)
▶$5.2MraisedJan 2025 · 48 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeff RossDirector
- Jeff LiterExecutive Officer, Director, Promoter
- John WellsDirector
- James HaymakerDirector, Promoter
- Tracey LodieDirector
- Mark ChanceDirector
- Offering amount
- $5.9M
- Amount sold
- $5.2M
- First sale
- Nov 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$375KraisedNov 2021 · 3 investors · BiotechnologyRule 506(b)
▶$375KraisedNov 2021 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jim HaymakerDirector
- David LargaespadaExecutive Officer, Director, Promoter
- Jeff LiterExecutive Officer, Director, Promoter
- John WellsDirector
- Tracey LodieDirector
- George CoxDirector
- Offering amount
- $1.5M
- Amount sold
- $375K
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$825KraisedFeb 2021 · 11 investors · Biotechnology
▶$825KraisedFeb 2021 · 11 investors · Biotechnology
Officers, directors & promoters on the filing
- Jim HaymakerDirector
- Tracey LodieDirector
- George CoxDirector
- John WellsDirector
- Jeff LiterExecutive Officer, Director, Promoter
- David LargaespadaExecutive Officer, Director, Promoter
- Offering amount
- $1M
- Amount sold
- $825K
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 04
▶$1.5MraisedNov 2019 · 11 investors · BiotechnologyRule 506(b)
▶$1.5MraisedNov 2019 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David LargaespadaExecutive Officer, Director, Promoter
- Jeff LiterExecutive Officer, Director, Promoter
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapKite Pharma23 shared keywordsKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.
Solu22 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Companies competing with Luminary Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Luminary Therapeutics do?
- Luminary Therapeutics is a clinical-stage biotech developing allogeneic CAR-T cell therapies built on its Gamma 2.0+ platform to treat solid tumors, B-cell malignancies, and B-cell-mediated autoimmune diseases. The company uses a Dual CAR architecture and the TcBuster transposon system to address relapse, T cell exhaustion, and high manufacturing costs.
- Who founded Luminary Therapeutics?
- Luminary Therapeutics was founded by David Largaespada in 2019.
- Who are Luminary Therapeutics's investors?
- Luminary Therapeutics's investors include CWRU Technology Ventures.
- How much funding has Luminary Therapeutics raised?
- Luminary Therapeutics has disclosed $14.5M raised across 6 rounds.
- Where is Luminary Therapeutics headquartered?
- Luminary Therapeutics is headquartered in Minneapolis, US.